Aequus Announces Zimed PF Website Launch
VANCOUVER, British Columbia, Aug. 22, 2023 (GLOBE NEWSWIRE) — Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF), ) (“Aequus” or the “Company”), a specialty pharmaceutical company, are thrilled to announce the launch of our user friendly education website for patients and professionals. With a focus on elevated, interocular pressure, Glaucoma and Dry Eye Disease, this website features Zimed® PF, the first preservative-free multi-dose Bimatoprost available in Canada. The response from Canadian physicians at the 2023 annual COS conference in Quebec City has been nothing short of exceptional.
Related news for (AQSZF)
- Aequus Reports Second Quarter 2023 Financial Highlights and General Update
- Aequus Announces Zimed PF Now Available in Canada
- Aequus Pharmaceutical Canada Announces a Pause in Sales of Evolve Intensive Eyedrops and Gel in Canada
- Aequus Announces Financing to Support Launch of Zimed Preservative Free (Bimatoprost 0.03%)
